Skip to main content
. 2023 Sep 10;21(3):15593258231200527. doi: 10.1177/15593258231200527

Figure 2.

Figure 2.

Target treatment for T2DM (DPP – 4i, dipeptidyl peptide – 4 inhibitor; TZDs, thiazolidinediones; SGLT-2i, sodium–glucose co-transporter 2 inhibitor; GLP-1RA, glucagon-like peptide – 1 receptor agonist). 20